| 28 September 2017

World Retina Day 2017

Retina International is sending a RED Alert – On World Retina Day 2017

Online Toolkit on Genetic Testing for Inherited Retinal Disease launched by Retina International on World Retina Day 2017.  

On World Retina Day, Saturday, September 30th 2017, Retina International together with its 43 member organisations and interested groups is sending a RED ALERT to local, national and regional groups.


| 24 September 2017

AMD Week 2017

AMD (Age-related Macular Degeneration) is a condition that affects central vision and is associated with aging. It is important to note however that deteriorating vision is not an inevitable part of the aging process but the result of a particular condition that can, when diagnosed early enough be successfully treated.

In the over 50s, AMD is the leading cause of sight loss.


| 24 August 2017

Member News: First Patient Enrolled in USH2A Natural History Study

Four-year study will follow patients at 20 clinical sites worldwide

The first patient has been enrolled in a four-year natural history study of people with mutations in the USH2A gene which are the leading cause of the combined vision and hearing loss associated with Usher syndrome type 2A and vision loss from autosomal recessive retinitis pigmentosa. There are currently no treatments for the vision loss associated with these inherited retinal diseases.


| 24 August 2017

Scientific Events: A Symposium in honor of Dr. Gustavo Aguirre FARVO, University of Pennsylvania , November 16th, 2017

A Symposium in honor of Dr. Gustavo Aguirre, recipient of the 2017 Proctor Medal, Association for Research in Vision and Ophthalmology (ARVO) will take place on Thursday November 16, 2017; 1:00pm—6:00pm at the School of Veterinary Medicine, University of Pennsylvania Please visit http://TRRaTConference.website2.me

Attendance is free but registration is essential to secure a place.


| 24 August 2017

Industry News: MeiraGTx Provides Clinical Trial Updates for X-Linked Retinitis Pigmentosa and Achromatopsia Gene Therapy Programs

 MeiraGTx, a New York and London based gene therapy company, have announced the first patient in its clinical study for X-Linked Retinitis Pigmentosa (XLRP) was treated at Moorfields Eye Hospital in London.  This clinical study is the first-in-man Phase I/II dose escalation study of AAV2/5-hRKp.RPGR, MeiraGTx’s AAV-mediated gene therapy for XLRP caused by mutations in the RP GTPase regulator gene (RPGR).


| 09 August 2017

Retina International Symposium: EURetina 2017

Retina International will host its annual EURetina Symposium from 9am to 10.30am on Thursday September 7th in room 124 of the Barcelona Convention Centre.

The symposium will feature presentations on the European Reference Network for Rare Eye Disease (ERN-EYE), results from a recent study on the Economic Burden of Blindness in Europe, Patient Reported Outcome Measures for the retina and an introduction to the Retina International toolkit on genetic testing.


| 25 July 2017

Members News: 4D Molecular Therapeutics and Foundation Fighting Blindness Partner to Develop Gene Therapies for Retinal Diseases

4D Molecular Therapeutics (4DMT), a leader in adeno-associated virus (AAV) gene therapy vector discovery and product development, and the Foundation Fighting Blindness (FFB), the world’s largest non-governmental source of research funding for inherited retinal degenerations (IRD) and dry age-related macular degeneration (AMD), today announced a partnership to develop intravitreal gene therapeutics for patients with these blinding conditions using 4DMT-proprietary AAV vectors.


| 17 July 2017

Industry News: Spark Therapeutics’ Biologics License Application for Investigational Voretigene Neparvovec Accepted for Filing by FDA

A massive step forward for the Retina Community as The FDA grants  a Priority Review with Prescription Drug User Fee Act (PDUFA) date of Jan. 12, 2018

LUXTURNATM (voretigene neparvovec) unveiled as proposed trade name.

Join Our Mailing List